It is based on developing bispecific antibody cancer programs.
ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Their core values are life-improvement, collaboration, innovation and novel therapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 31, 2017 | Series B | ₩20B | 2 | — | — | Detail |
Jul 19, 2016 | Series A | ₩9B | 1 |
|
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
|
Yes | Series A |
|
— | Series B |
|
— | Series B |